Global impression of perceived difficulties in children and adolescents with attention-deficit/hyperactivity disorder: Reliability and validity of a new instrument assessing perceived difficulties from a patient, parent and physician perspective over the day

Child and Adolescent Psychiatry and Mental Health

Volumn 2, Issue , 2008, Pages

  Wehmeier, Peter M ^a   Schacht, Alexander ^a   Dittmann, Ralf W ^a,b   Döpfner, Manfred ^c  

^a LILLY DEUTSCHLAND GMBH   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; DISCRIMINANT VALIDITY; DRUG DOSE INCREASE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; GLOBAL IMPRESSION OF PERCEIVED DIFFICULTIES; HUMAN; MAJOR CLINICAL STUDY; MORNING DOSAGE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; RATING SCALE; RECOMMENDED DRUG DOSE; SOCIAL PSYCHOLOGY; TEST RETEST RELIABILITY;

EID: 45149099529     PISSN: None     EISSN: 17532000     Source Type: Journal    
DOI: 10.1186/1753-2000-2-10     Document Type: Article

References (49)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) Washington, DC, American Psychiatric Association 2000
2. Barkley RA: Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002(Suppl 12):10-15.
3. Biederman J Faraone SV: Attention-deficit hyperactivity disorder. Lancet 2005, 366:237-248. 10.1016/S0140-6736(05)66915-2 16023516
4. Escobar R Soutullo CA Hervas A Gastaminza X Polavieja P Gilaberte I: Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 2005, 116:e364-e369. 10.1542/peds.2005-0386 16140679
5. Harpin VA: The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child 2007 (Suppl 1):i2-i7.
6. Klassen AF Miller A Fine S: Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics 2004, 114:e541-e547. 10.1542/peds.2004-0844 15520087
7. Matza LS Rentz AM Secnik K Swensen AR Revicki DA Michelson D Spencer T Newcorn JH Kratochvil CJ: The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2004, 25:166-174. 10.1097/ 00004703-200406000-00005 15194901
8. Riley AW Spiel G Coghill D Döpfner M Falissard B Lorenzo MJ Preuss U Ralston SJ: ADORE Study Group Factors related to Health-Related Quality of Life (HRQoL) among children with ADHD in Europe at entry into treatment. Eur Child Adolesc Psychiatry 2006, (Suppl 1):i38-i45. 10.1007/ s00787-006-1006-9
9. Sawyer MG Whaites L Rey JM Hazell PL Graetz BW Baghurst P: Health-related quality of life of children and adolescents with mental disorders. J Am Acad Child Adolesc Psychiatry 2002, 41: 530-537. 10.1097/ 00004583-200205000-00010 12014785
10. Jensen PS Hinshaw SP Swanson JM Greenhill LL Conners CK Arnold LE Abikoff HB Elliott G Hechtman L Hoza B March JS Newcorn JH Severe JB Vitiello B Wells K Wigal T: Findings from the NIMH multimodal treatment study of ADHD (MTA): Implications and applications for primary care providers. Dev Behav Pediatrics 2001, 22(1):60-73.
11. Döpfner M Breuer D Schürmann S Metternich TW Rademacher C Lehmkuhl G: Effectiveness of an adaptive multimodal treatment in children with Attention-Deficit Hyperactivity Disorder - global outcome. Eur Child Adolesc Psychiatry 2004 (Suppl 1):I117-I129.
12. Banaschewski T Roessner V Dittmann RW Santosh PJ Rothenberger A: Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004, (Suppl 1):I102-I116.
13. Becker K Wehmeier PM Schmidt MH: The Noradrenergic Transmitter System in ADHD: Principles and Implications for Treatment. Stuttgart (Germany): Thieme 2006
14. Kelsey DK Sumner CR Casat CD Coury DL Quintana H Saylor KE Sutton VK Gonzales J Malcolm SK Schuh KJ Allen AJ: Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics 2004, 114:e1-e8. 10.1542/ peds.114.1.e1 15231966
15. Michelson D Allen AJ Busner J Casat C Dunn D Kratochvil C Newcorn J Sallee FR Sangal RB Saylor K West S Kelsey D Wernicke J Trapp NJ Harder D: Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry 2002, 159:1896-1901. 10.1176/ appi.ajp.159.11.1896 12411225
16. Michelson D Faries D Wernicke J Kelsey D Kendrick K Sallee FR Spencer T: Atomoxetine ADHD Study Group Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 2001, 108:e83 e91. 10.1542/peds.108.5.e83 11694667
17. Spencer T Heiligenstein JH Biederman J Faries DE Kratochvil CJ Conners CK Potter WZ: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002, 63:1140-1147. 12523874
18. Cheng JYW Chen RYL Ko JSN Ng EML: Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents. Meta-analysis and meta-regression analysis. Psychopharmacology (Berl) 2007, 194:197-209. 10.1007/s00213-007-0840-x 17572882
19. Brown RT Perwien A Faries DE Kratochvil CJ Vaughan BS: Atomoxetine in the management of children with ADHD: Effects on quality of life and school functioning. Clin Pediatr (Phila) 2006, 45:819-827. 17041169
20. Buitelaar JK Danckaerts M Gillberg C Zuddas A Becker K Bouvard M Fagan J Gadoros J Harpin V Hazell P Johnson M Lerman-Sagie T Soutullo CA Wolanczyk T Zeiner P Fouche DS Krikke-Workel J Zhang S Michelson D: Stomoxetine International Study Group A prospective, multi-center, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur Child Adolesc Psychiatry 2004, 13:249-257. 15365896
21. Matza LS Stoeckl MN Shorr JM Johnston JA: Impact of atomoxetine on health-related quality of life and functional status in patients with ADHD. Expert Rev Pharmacoeconomics Outcomes Res 2006, 6:379-390. 10.1586/ 14737167.6.4.379
22. Perwien AR Kratochvil CJ Faries DE Vaughan BS Spencer T Brown RT: Atomoxetine Treatment in Children and Adolescents with Attention-Deficit Hyperactivity Disorder: What Are the Long-Term Health-Related Quality-of-Life Outcomes?. J Child Adolesc Psychopharmacol 2006, 16:713-724. 10.1089/cap.2006.16.713 17201615
23. Perwien AR Faries DE Kratochvil CJ Sumner CR Kelsey DK Allen AJ: Improvement in health-related quality of life in children with ADHD: An analysis of placebo controlled studies of atomoxetine. J Dev Behav Pediatr 2004, 25:445. 10.1097/00004703-200408000-00006 15613996
24. Prasad S Harpin V Poole L Zeitlin H Jamdar S Puvanendran K: The SUNBEAM Study Group A multicentre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin 2007, 23:379-394. 10.1185/030079906X167309 17288692
25. Wehmeier PM Dittmann RW Schacht A Minarzyk A Lehmann M Sevecke K Lehmkuhl G: Effectiveness of atomoxetine in children with attention-deficit/hyperactivity disorder and quality of life as perceived by patients, parents and physicians in an open-label study. J Child Adolesc Psychopharmacol 2007, 17:813-829. 10.1089/cap.2007.0025 18315453
26. DuPaul GJ Power TJ Anastopoulos AD Reid R: ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York (NY): Guilford 1998
27. Faries DE Yalcin I Harder D Heiligenstein JH: Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord 2001, 5:39-47. 10.1177/108705470100500204
28. Guy W: ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC: US Department of Health, Education and Welfare 1976:218-222.
29. National Institutes of Mental Health (NIMH): Psychopharmacology Bulletin 1985, 21:839-943.
30. Landgraf J Abetz L Ware J: Child Health Questionnaire (CHQ): A Users Manual. Boston: Integrated Therapeutics Group 1996
31. Klassen AF Miller A Fine S: Agreement between parent and child report of quality of life in children with attention-deficit/hyperactivity disorder. Child Care Health Dev 2006, 32:397-406. 10.1111/ j.1365-2214.2006.00609.x 16784495
32. Dittmann RW Wehmeier PM Lehmann M Schacht A Helsberg K Lehmkuhl G: Behandlung von ADHS bei Jugendlichen in Deutschland: Offene Studie zur Effektivität und Verträglichkeit von Atomoxetin aus Sicht von Arzt, Eltern und Patient. Nervenarzt 2006(Suppl 3):S300.
33. Döpfner M Steinhausen HC Coghill D Dalsgaard S Poole L Ralston SJ Rothenberger A: The ADORE Study Group Cross-cultural reliability and validity of ADHD assessed by the ADHD Rating Scale in a pan-European study. Eur Child Adolesc Psychiatry 2006(Suppl 1):I/46 I/55
34. Connolly MA Johnson JA: Measuring quality of life in paediatric patients. Pharmacoeconomics 1999, 16:605-625. 10.2165/ 00019053-199916060-00002 10724790
35. Eiser C Morse R: A review of measures of quality of life for children with chronic illness. Arch Dis Child 2001, 84:205-211. 1718699 11207164 10.1136/adc.84.3.205
36. Raat H Bonsel GJ Essink-Bot ML Landgraf JM Gemke RJBJ: Reliability and validity of comprehensive health status measures in children: The Child Health Questionnaire in relation to the Health Utilities Index. J Clin Epidemiol 2002, 55:67-76. 10.1016/S0895-4356(01)00411-5 11781124
37. Schmidt LJ Garratt AM Fitzpatrick R: Child/parent-assessed population health outcome measures: A structured review. Child Care Health Dev 2002, 28(3):227-237. 10.1046/j.1365-2214.2002.00266.x 12064288
38. Hakkaart-van Roijen L Zwirs BWC Bouwmans C Tan SS Schulpen TWJ Vlasveld L Buitelaar JK: Societal costs and quality of life of children suffering from attention deficit hyperactivity disorder (ADHD). Eur Child and Adolesc Psychiatry 2007, 16(5):316-326. 10.1007/s00787-007-0603-6
39. Landgraf JM Rich M Rappaport L: Measuring quality of life in children with attention-deficit/hyperactivity disorder and their families. Arch Pediatr Adolesc Med 2002, 156:384-391. 11929374
40. Rentz AM Matza LS Secnik K Swensen A Revicki DA Psychometric validation of the child health questionnaire (CHQ) in a sample of children and adolescents with attention-deficit/hyperactivity disorder. Qual Life Res 2005, 14:719-734. 10.1007/s11136-004-0832-9 16022065
41. Varni JW Burwinkle TM: The PedsQL as a patient-reported outcome in children and adolescents with attention-deficit/hyperactivity disorder: a population-based study. Health and Qual Life Outcomes 2006, 4:26-35. 10.1186/1477-7525-4-26
42. Döpfner M Lehmkuhl G: DISYPS-JK: Diagnostik-System für psychische Störungen im Kindes- und Jugendalter nach ICD-10 und DSM-IV Bern (Switzerland): Verlag Hans Huber 2000.
43. Sutton V Summer C Allen AJ Feng W Schuh K Michelson D Validity, reliability, and responsiveness of the DPREMB-R scale for ADHD [abstract] Scientific Proceedings of the 50th Anniversary Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Miami Beach, USA, 14th-19th October, 2003:169-170.
44. Landgraf JM Maunsell E Nixon-Speechley K Bulllinger M Campbell S Abetz L Ware JE: Canadian-French, German, and United Kingdom versions of the Child Health Questionnaire (CHQ-PF50): Methodology and preliminary item scaling results. Qual Life Res 1998, 7:433-445. 10.1023/A:1008810004694 9691723
45. Riley AW Forrest CB Starfield B Green BF Robertson JA Friello P: The parent report form of the CHIP-Child Edition. Reliability and Validity. Medical Care 2004, 42:210-220. 10.1097/01.mlr.0000114909.33878.ca 15076820
46. Mattejat F Remschmidt H: Die Erfassung des Therapieerfolges in der Kinder- und Jugendpsychiatrie unter naturalistischen Bedingungen. Konzeption und Realisierung des Marburger Systems zur Qualitätssicherung und Therapieevaluation (MARSYS). Z Kinder Jugendpsychiatr Psychother 2006, 34:445-454. 10.1024/1422-4917.34.6.445 17094063
47. Remschmidt H Mattejat F: Wie erfolgreich sind stationäre kinder- und jugendpsychiatrische Behandlungen? Erste Ergebnisse aus dem Marburger Evaluationsprojekt. Z Kinder Jugendpsychiatr Psychother 2006, 34:455-464. 10.1024/1422-4917.34.6.455 17094064
48. Achenbach TM McConaughy SH Howell CT: Child/adolescent behavioral and emotional problems: Implications of cross-informant correlations for situational specifity. Psychological Bulletin 1987, 101:213-232. 10.1037/ 0033-2909.101.2.213 3562706
49. Plück J Döpfner M Berner W Fegert J Huss M Lenz K Schmeck K Lehmkuhl U Poustka F Lehmkuhl G: Die Bedeutung unterschiedlicher Informationsquellen bei der Beurteilung psychischer Störungen im Jugendalter - ein Vergleich von Elternurteil und Selbsteinschätzung der Jugendlichen. Praxis der Kinderpsychologie und Kinderpsychiatrie 1997, 46:566-582. 9454236